Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a
Benzimidazoles
/ pharmacology
Cystadenocarcinoma, Serous
/ genetics
Drug Resistance, Neoplasm
/ genetics
Female
Humans
Middle Aged
Mutation
Ovarian Neoplasms
/ genetics
Protein Kinase Inhibitors
/ therapeutic use
Proto-Oncogene Proteins c-myc
/ genetics
Proto-Oncogene Proteins p21(ras)
/ genetics
Receptor, ErbB-3
/ genetics
Signal Transduction
ras Proteins
/ genetics
ovarian neoplasm
Journal
Cold Spring Harbor molecular case studies
ISSN: 2373-2873
Titre abrégé: Cold Spring Harb Mol Case Stud
Pays: United States
ID NLM: 101660017
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
15
05
2019
accepted:
01
10
2019
entrez:
15
12
2019
pubmed:
15
12
2019
medline:
22
8
2020
Statut:
epublish
Résumé
Low-grade serous ovarian cancer (LGSOC) is relatively chemoresistant, and no precision therapy is approved for this indication. Despite promising results in phase II trials, MEK inhibitors have failed to show improved progression-free survival in a phase III trial when compared to physician's choice chemotherapy. We report for the first time temporal changes in the tumor genome assessed in sequential tumor samples of a 48-yr-old patient with a
Identifiants
pubmed: 31836588
pii: mcs.a004341
doi: 10.1101/mcs.a004341
pmc: PMC6913142
pii:
doi:
Substances chimiques
Benzimidazoles
0
KRAS protein, human
0
MYC protein, human
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins c-myc
0
binimetinib
181R97MR71
ERBB3 protein, human
EC 2.7.10.1
Receptor, ErbB-3
EC 2.7.10.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
ras Proteins
EC 3.6.5.2
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2019 Colombo et al.; Published by Cold Spring Harbor Laboratory Press.
Références
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Gynecol Oncol Rep. 2018 May 24;25:41-44
pubmed: 29946554
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Gynecol Oncol Res Pract. 2016 May 05;3:5
pubmed: 27231576
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S9-13
pubmed: 25341587
Lancet Oncol. 2013 Feb;14(2):134-40
pubmed: 23261356
Neoplasia. 2019 Jun;21(6):582-590
pubmed: 31054497
Cancer Cell Int. 2019 Jan 8;19:10
pubmed: 30636931
Obstet Gynecol. 2006 Aug;108(2):361-8
pubmed: 16880307
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cell Rep. 2014 Apr 10;7(1):86-93
pubmed: 24685132
Gynecol Oncol. 2017 Feb;144(2):250-255
pubmed: 28062115
Clin Cancer Res. 2018 Oct 1;24(19):4874-4886
pubmed: 29959144
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
pubmed: 24078660
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Oncotarget. 2015 Nov 10;6(35):37663-77
pubmed: 26506417
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179
Am J Cancer Res. 2016 Oct 01;6(10):2235-2251
pubmed: 27822414
Gynecol Oncol. 2014 Jun;133(3):401-4
pubmed: 24878391
Gynecol Oncol. 2016 Dec;143(3):532-538
pubmed: 27717490